Manhattan Associates, Inc. (MANH)
Live price chart, market sentiment, and community perspectives for Manhattan Associates, Inc. (NASDAQ: MANH).
Live price chart, market sentiment, and community perspectives for Manhattan Associates, Inc. (NASDAQ: MANH).
On our desk, we are evaluating the recent single-day 20%+ gain alongside the broader context. Even with the strong Q2 2026 beat—reporting adjusted EPS of $1.39 on $297.8 million in revenue—we note that MANH has underperformed broader tech and mid-cap benchmarks since August 2024. The valuation remains a primary talking point, especially considering the historical 63x earnings multiple that triggered previous hold ratings across the street.
When analyzing warehouse and logistics software deployments for retail and manufacturing clients, we have to look at how sticky these solutions are. Manhattan's core capability in orchestrating millions of items in complex distribution centers provides deep operational moats. Yet, candidates must understand that despite the third consecutive record bookings quarter, large deal delays continue to introduce lumpy revenue patterns that risk analysts scrutinize closely.
Looking closely at the underlying metrics from the latest reports, the 23% year-over-year growth in remaining performance obligations (RPO) up to $2.47 billion gives us tangible proof of enterprise demand for their supply chain optimization software. However, the macro consensus remains mixed, with several automated screening panels warning about potential margin compression and normalization of cloud adoption rates.
Reviewing the July 2026 option chains, we spotted a max pain price calculated around $140.00 with a wide 50-point gap separating peak call and put strikes. The options landscape shows a call-dominant distribution, but given that retail sentiment hovers near a neutral 55% constructive score, we are advising clients to watch for potential consolidation rather than chasing the recent post-earnings pop blindly.
From a quantitative perspective, social sentiment aggregation across StockTwits and X shows mild bullishness, but engagement velocity indicates a lack of aggressive retail momentum. With Q2 2026 non-GAAP earnings beating consensus by over 6%, the fundamental business is executing well, but the elevated valuation multiple leaves little room for operational error in the upcoming quarters.
Explore plasma cleansing, somatic organ swaps, and BCI.